In a high-stakes gamble that could reshape the oncology landscape, Danish biotechnology powerhouse Genmab AS announced Monday it will acquire Dutch clinical-stage biotech firm Merus NV in a bold, all-cash deal worth roughly $8 billion. Advising the parties are some of the world’s legal heavyweights: Allen Overy Shearman Sterling and Kromann Reumert for Genmab, with Latham & Watkins LLP and NautaDutilh representing Merus.

The agreement sets the stage for Genmab to launch a tender offer for 100% of Merus’ shares, with the finish line expected in the first quarter of 2026, pending regulatory and customary conditions. Merus confirmed the deal requires at least 80% shareholder acceptance, though Genmab may lower the bar to 75% if conditions are met.

Boards Aligned, Strategy Clear

Both companies’ boards unanimously approved the transaction, a ringing endorsement of Genmab’s strategy to accelerate its shift toward a wholly-owned model. The acquisition aims to diversify revenue streams and reinforce Genmab’s march toward sustained, long-term growth.

Dr. Jan van de Winkel, Genmab’s president and CEO, didn’t mince words:
“This acquisition aligns seamlessly with our long-term vision. It has the power to propel Genmab into a new era as a global biotechnology leader, fueling durable growth well into the next decade.”

Petosemtamab: The Crown Jewel

At the center of the deal lies petosemtamab, Merus’ flagship therapy—a late-stage EGFRxLGR5 bispecific antibody for head and neck cancer. Currently in Phase 3 trials, the drug has already earned two breakthrough therapy designations from the U.S. Food and Drug Administration.

Van de Winkel called the asset “transformational,” stressing Genmab’s confidence in its ability to unlock the therapy’s promise for patients while leveraging its proven commercialization track record. If all goes to plan, Genmab projects an initial launch by 2027, pending clinical trial outcomes and regulatory green lights.

Financing and Market Reaction

To bankroll the megadeal, Genmab will lean on existing cash and secure about $5.5 billion in nonconvertible debt through Morgan Stanley Senior Funding Inc. Investors cheered the move, sending Merus stock soaring nearly 36% Monday, while the purchase price reflected a 41% premium over Friday’s close of $68.89, and a 44% premium over its 30-day weighted average.

Merus CEO Sees Bright Future

For Merus, the acquisition is both validation and opportunity. Dr. Bill Lundberg, president and CEO, said:
“We are thrilled to join Genmab, a pioneer in antibody therapeutics. Together, we will advance petosemtamab for patients battling head and neck cancer and beyond.”

He added that the companies’ shared legacy of innovation in multispecific antibodies makes Genmab the right partner to take the program across the finish line.

A Signal to the Biotech Market

The deal also reverberated beyond the two companies. International Biotechnology Trust PLC, which counts Genmab among its portfolio companies, celebrated its 32nd M&A transaction since 2020. Portfolio managers Ailsa Craig and Marek Poszepczynski suggested the move underscores oncology’s dominant role in fueling biotech returns.

Their statement hinted at momentum: “Clusters of acquisition activity often emerge around key industry events. This could be the start of a welcome surge in deals.”

Legal Titans on the Field

The high-profile merger drew a who’s-who of international counsel. Genmab’s A&O Shearman team was spearheaded by Clare O’Brien and Derrick Lott, alongside a deep bench of partners including Harald Halbhuber, Michael Chernick, Jessica Delbaum, Jonathan Cheng, Doreen Lilienfeld, Matthew Brown, Christiaan de Brauw, Olivier Valk, and Rens Bondrager. Deal team details for the other firms remain under wraps.